Neurodegenerative diseases: New concepts of pathogenesis and their therapeutic implications

Annual Review of Pathology

Volumn 1, Issue , 2006, Pages 151-170

  Skovronsky, Daniel M ^a   Lee, Virginia M Y ^b   Trojanowski, John Q ^b  

^a AVID RADIOPHARMACEUTICALS   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alzheimer's disease; Amyloid; Misfolding; Neurodegeneration; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; BETA SECRETASE; BETA SECRETASE INHIBITOR; CLIOQUINOL; FLURBIPROFEN; GAMMA SECRETASE INHIBITOR; GLYCOSAMINOGLYCAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ROTENONE;

ALZHEIMER DISEASE; AMYLOIDOSIS; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; HUMAN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW;

EID: 33645728523     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev.pathol.1.110304.100113     Document Type: Review

References (127)

1. Hebert LE, Beckett LA, Scherr PA, Evans DA. 2001. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis. Assoc. Disord. 15:169-73
2. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. 2003. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 60:1119-22
3. Brookmeyer R, Gray S, Kawas C. 1998. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health 88:1337-42
4. Samii A, Nutt JG, Ransom BR. 2004. Parkinson's disease. Lancet 363:1783-93
5. Ernst RL, Hay JW, Fenn C, Tinklenberg J, Yesavage JA. 1997. Cognitive function and the costs of Alzheimer disease. An exploratory study. Arch. Neurol. 54:687-93
6. Forman MS, Trojanowski JQ, Lee VM. 2004. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat. Med. 10:1055-63
7. Caughey B, Lansbury PT. 2003. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26:267-98
8. Huang TH, Yang DS, Plaskos NP, Go S, Yip CM, et al. 2000. Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide. J. Mol. Biol. 297:73-87
9. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. 2000. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 39:10831-39
10. Podlisny MB, Walsh DM, Amarante P, Ostaszewski BL, Stimson ER, et al. 1998. Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. Biochemistry 37:3602-11
11. Takahashi RH, Almeida CG, Kearney PF, Yu F, Lin MT, et al. 2004. Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J. Neurosci. 24:3592-99
12. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, et al. 2003. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486-89
13. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, et al. 2003. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300:636-40
14. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, et al. 2005. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307:1282-88
15. Hiruma H, Katakura T, Takahashi S, Ichikawa T, Kawakami T. 2003. Glutamate and amyloid beta-protein rapidly inhibit fast axonal transport in cultured rat hippocampal neurons by different mechanisms. J. Neurosci. 23:8967-77
16. Roy S, Zhang B, Lee VM, Trojanowski JQ. 2005. Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropathol. 109:5-13
17. Morfini G, Pigino G, Brady ST. 2005. Polyglutamine expansion diseases: failing to deliver. Trends Mol. Med. 11:64-70
18. Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA. 2001. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 21:9549-60
19. Tanaka Y, Engelender S, Igarashi S, Rao RK, Wanner T, et al. 2001. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10:919-26
20. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, et al. 2001. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413:739-43
21. Behl C, Davis JB, Lesley R, Schubert D. 1994. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77:817-27
22. Stefanova N, Reindl M, Neumann M, Haass C, Poewe W, et al. 2005. Oxidative stress in transgenic mice with oligodendroglial {alpha}-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am. J. Pathol. 166:869-76
23. Nakagawa T, Zhu H, Morishima N, Li E, Xu J, et al. 2000. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 403:98-103
24. Xu J, Kao SY, Lee FJ, Song W, Jin LW, Yankner BA. 2002. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8:600-6
25. Brown DF, Risser RC, Bigio EH, Tripp P, Stiegler A, et al. 1998. Neocortical synapse density and Braak stage in the Lewy body variant of Alzheimer disease: a comparison with classic Alzheimer disease and normal aging. J. Neuropathol. Exp. Neurol. 57:955-60
26. Brown DF, Dababo MA, Bigio EH, Risser RC, Eagan KP, et al. 1998. Neuropathologic evidence that the Lewy body variant of Alzheimer disease represents coexistence of Alzheimer disease and idiopathic Parkinson disease. J. Neuropathol. Exp. Neurol. 57:39-46
27. Lippa CF, Fujiwara H, Mann DM, Giasson B, Baba M, et al. 1998. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am. J. Pathol. 153:1365-70
28. Hamilton RL. 2000. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 10:378-84
29. Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ. 1999. Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann. Neurol. 45:353-57
30. Sebeo J, Hof PR, Perl DP. 2004. Occurrence of alpha-synuclein pathology in the cerebellum of Guamanian patients with parkinsonism-dementia complex. Acta Neuropathol. 107:497-503
31. Duda JE, Giasson BI, Mabon ME, Miller DC, Golbe LI, et al. 2002. Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol. 104:7-11
32. Saito Y, Suzuki K, Hulette CM, Murayama S. 2004. Aberrant phosphorylation of alpha-synuclein in human Niemann-Pick type C1 disease. J. Neuropathol. Exp. Neurol. 63:323-28
33. Saito Y, Suzuki K, Nanba E, Yamamoto T, Ohno K, Murayama S. 2002. Niemann-Pick type C disease: accelerated neurofibrillary tangle formation and amyloid beta deposition associated with apolipoprotein E epsilon 4 homozygosity. Ann. Neurol. 52:351-55
34. Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-56
35. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, et al. 1991. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349:704-6
36. Scheuner D, Eckman C, Jensen M, Song X, Citron M, et al. 1996. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2:864-70
37. Wolfe MS, Xia W, Moore CL, Leatherwood DD, Ostaszewski B, et al. 1999. Peptidomimetic probes and molecular modeling suggest that Alzheimer's gamma-secretase is an intramembrane-cleaving aspartyl protease. Biochemistry 38:4720-27
38. Yankner BA. 1996. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 16:921-32
39. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, et al. 2003. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486-89
40. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. 2002. Tau is essential to beta-amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. USA 99:6364-69
41. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, et al. 2001. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293:1487-91
42. Mann DM, Brown A, Prinja D, Davies CA, Landon M, et al. 1989. An analysis of the morphology of senile plaques in Down's syndrome patients of different ages using immunocytochemical and lectin histochemical techniques. Neuropathol. Appl. Neurobiol. 15:317-29
43. Lemere CA, Lopera F, Kosik KS, Lendon CL, Ossa J, et al. 1996. The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat. Med. 2:1146-50
44. Smith MJ, Kwok JB, McLean CA, Kril JJ, Broe GA, et al. 2001. Variable phenotype of Alzheimer's disease with spastic paraparesis. Ann. Neurol. 49:125-29
45. Morris JC, Storandt M, McKeel DW Jr, Rubin EH, Price JL, et al. 1996. Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease. Neurology 46:707-19
46. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, et al. 2000. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283:1571-77
47. Golde TE. 2003. Alzheimer disease therapy: can the amyloid cascade be halted? J. Clin. Invest. 111:11-18
48. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, et al. 2001. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. Mol. Genet. 10:1317-24
49. Gruninger-Leitch F, Schlatter D, Kung E, Nelbock P, Dobeli H. 2002. Substrate and inhibitor profile of BACE (beta-secretase) and comparison with other mammalian aspartic proteases. J. Biol. Chem. 277:4687-93
50. Hong L, Koelsch G, Lin X, Wu S, Terzyan S, et al. 2000. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 290:150-53
51. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, et al. 1999. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402:537-40
52. Li Y-M, Xu M, Lai M-T, Huang Q, Castro JL, et al. 2000. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405:689-94
53. Wolfe MS, Esler WP, Das C. 2002. Continuing strategies for inhibiting Alzheimer's gamma-secretase. J. Mol. Neurosci. 19:83-87
54. Esler WP, Kimberly WT, Ostaszewski BL, Diehl TS, Moore CL, et al. 2000. Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat. Cell Biol. 2:428-34
55. De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, et al. 1999. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 398:518-22
56. Ni C-Y, Murphy MP, Golde TE, Carpenter G. 2001. gamma-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294:2179-81
57. Phiel CJ, Wilson CA, Lee VMY, Klein PS. 2003. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423:435-39
58. Schenk D. 2004. Hopes remain for an Alzheimer's vaccine. Nature 431:398
59. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, et al. 1999. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173-77
60. Bard F, Cannon C, Barbour R, Burke RL, Games D, et al. 2000. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:916-19
61. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, et al. 2000. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408:979-82
62. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, et al. 2000. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982-85
63. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. 2003. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9:448-52
64. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, et al. 2003. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61:46-54
65. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, et al. 2003. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38:547-54
66. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, et al. 2001. A subset of NSAIDs lower amyloidogenic A[beta]42 independently of cyclooxygenase activity. Nature 414:212-16
67. Lim GP, Yang F, Chu T, Chen P, Beech W, et al. 2000. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20:5709-14
68. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, et al. 2003. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta42 in vivo. J. Clin. Invest. 112:440-49
69. Stewart WF, Kawas C, Corrada M, Metter EJ. 1997. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48:626-32
70. Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB. 1995. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 45:1092-96
71. Puglielli L, Tanzi RE, Kovacs DM. 2003. Alzheimer's disease: the cholesterol connection. Nat. Neurosci. 6:345-51
72. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. 2000. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57:1439-43
73. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. 2000. Statins and the risk of dementia. Lancet 356:1627-31
74. Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, et al. 2002. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann. Neurol. 52:346-50
75. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, et al. 2002. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623-30
76. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, et al. 2000. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7:321-31
77. Frears ER, Stephens DJ, Walters CE, Davies H, Austen BM. 1999. The role of cholesterol in the biosynthesis of beta-amyloid. NeuroReport 10:1699-705
78. Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, et al. 2001. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8:890-99
79. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. 1998. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA 95:6460-64
80. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, et al. 2001. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98:5856-61
81. Cherny RA, Legg JT, McLean CA, Fairlie DP, Huang X, et al. 1999. Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J. Biol. Chem. 274:23223-28
82. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, et al. 2001. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30:665-76
83. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, et al. 2003. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 60:1685-91
84. Gervais F, Chalifour R, Garceau D, Kong X, Laurin J, et al. 2001. Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid 1(Suppl. 8):28-35
85. Geerts H. 2004. NC-531 (Neurochem). Curr. Opin. Investig. Drugs 5:95-100
86. Goedert M, Crowther RA, Spillantini MG. 1998. Tau mutations cause frontotemporal dementias. Neuron 21:955-58
87. Clark LN, Poorkaj P, Wszolek Z, Geschwind DH, Nasreddine ZS, et al. 1998. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc. Natl. Acad. Sci. USA 95:13103-7
88. Houlden H, Baker M, Morris HR, MacDonald N, Pickering-Brown S, et al. 2001. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 56:1702-6
89. Lee VM, Kenyon TK, Trojanowski JQ. 2005. Transgenic animal models of tauopathies. Biochim. Biophys. Acta 1739:251-59
90. Goedert M, Jakes R. 2005. Mutations causing neurodegenerative tauopathies. Biochim. Biophys. Acta 1739:240-50
91. D'Souza I, Poorkaj P, Hong M, Nochlin D, Lee VM, et al. 1999. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc. Natl. Acad. Sci. USA 96:5598-603
92. Hasegawa M, Smith MJ, Goedert M. 1998. Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett. 437:207-10
93. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, et al. 1998. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282:1914-17
94. Goedert M, Jakes R, Crowther RA. 1999. Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments. FEBS Lett. 450:306-11
95. Lee VM, Daughenbaugh R, Trojanowski JQ. 1994. Microtubule stabilizing drugs for the treatment of Alzheimer's disease. Neurobiol. Aging 15(Suppl. 2):S87-89
96. Ishihara T, Hong M, Zhang B, Nakagawa Y, Lee MK, et al. 1999. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24:751-62
97. Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, et al. 2005. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc. Natl. Acad. Sci. USA 102:227-31
98. Wischik CM, Edwards PC, Lai RYK, Roth M, Harrington CR. 1996. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc. Natl. Acad. Sci. USA 93:11213-18
99. Taniguchi S, Suzuki N, Masuda M, Hisanaga S-I, Iwatsubo T, et al. 2005. Inhibition of heparin-induced Tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 280:7614-23
100. Chirita C, Necula M, Kuret J. 2004. Ligand-dependent inhibition and reversal of tau filament formation. Biochemistry 43:2879-87
101. Pickhardt M, Gazova Z, von Bergen M, Khlistunova I, Wang Y, et al. 2005. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J. Biol. Chem. 280:3628-35
102. Bhat RV, Budd Haeberlein SL, Avila J. 2004. Glycogen synthase kinase 3: a drug target for CNS therapies. J. Neurochem. 89:1313-17
103. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-47
104. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. 1997. Alpha-synuclein in Lewy bodies. Nature 388:839-40
105. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. 1998. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA 95:6469-73
106. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, et al. 1998. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152:879-84
107. Tu PH, Galvin JE, Baba M, Giasson B, Tomita T, et al. 1998. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann. Neurol. 44:415-22
108. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, et al. 2003. alpha-synuclein locus triplication causes Parkinson's disease. Science 302:841
109. Eriksen JL, Dawson TM, Dickson DW, Petrucelli L. 2003. Caught in the act: alpha-synuclein is the culprit in Parkinson's disease. Neuron 40:453-56
110. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. 2002. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34:521-33
111. Maries E, Dass B, Collier TJ, Kordower JH, Steece-Collier K. 2003. The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat. Rev. Neurosci. 4:727-38
112. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, et al. 2000. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287:1265-69
113. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U. 2002. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J. Neurol. 249(Suppl. 3):III/1-5
114. Gibb WR, Lees AJ. 1988. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 51:745-52
115. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. 1998. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50:1346-50
116. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. 2000. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3:1301-6
117. Giasson BI, Lee VM. 2000. A new link between pesticides and Parkinson's disease. Nat. Neurosci. 3:1227-28
118. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, et al. 2000. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290:985-89
119. Ischiropoulos H, Beckman JS. 2003. Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J. Clin. Invest. 111:163-69
120. Bodles AM, El-Agnaf OM, Greer B, Guthrie DJ, Irvine GB. 2004. Inhibition of fibril formation and toxicity of a fragment of alpha-synuclein by an N-methylated peptide analogue. Neurosci. Lett. 359:89-93
121. El-Agnaf OM, Paleologou KE, Greer B, Abogrein AM, King JE, et al. 2004. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB J. 18:1315-17
122. Lee EN, Cho HJ, Lee CH, Lee D, Chung KC, Paik SR. 2004. Phthalocyanine tetrasulfonates affect the amyloid formation and cytotoxicity of alpha-synuclein. Biochemistry 43:3704-15
123. Fornai F, Lenzi P, Gesi M, Ferrucci M, Lazzeri G, et al. 2003. Recent knowledge on molecular components of Lewy bodies discloses future therapeutic strategies in Parkinson's disease. Curr. Drug Targets CNS Neurol. Disord. 2:149-52
124. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr. 2001. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294:1346-49
125. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. 2002. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295:865-68
126. Auluck PK, Meulener MC, Bonini NM. 2005. Mechanisms of suppression of {alpha}-synuclein neurotoxicity by geldanamycin in Drosophila. J. Biol. Chem. 280:2873-78
127. Rekas A, Adda CG, Aquilina JA, Barnham KJ, Sunde M, et al. 2004. Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity. J. Mol. Biol. 340:1167-83